Just a few thoughts on the discussion this morning,

With respect to billionaire timelines, I would agree to a degree that they wouldn't feel the pressure of time the same way many retail investors do but at the same time I think everyone from investors to management all know that the the IP at potential competitors is developing despite our oft refferred to "8 yr head start" and RVX needs to keep progressing to stay out front. Unneccessary foot dragging from alterior shennanigans would be to the peril of everyone including the large investors. I think the biggest time consumer right now is probably that RVX wants to get BETonMACE exactly right and going back and forth with the FDA is likely no easy task. Additionally, I'm pretty sure that we are all getting older at the same time rate :) but I do feel for older investors who have been in this along time and would like to see something come of it.

With respesct to the sharing of information, as I said in an earlier post, I think that retail investors have all the same material information that the big investors have but we do not have even close to the same access to the detail behind the material information that they would have. Much of this detail would likely have been closely looked at by scientists on the Eastern and Hepalink teams. We all should feel some level of comfort that after their professional DD they continue to invest. I imagine that only non-disclosures would allow for most sharing of this nature. Additionally we most likely do not get close to the same same level of progress reports that large investors would have access to until such time that this information becomes material. For example I imagine that KD can at any time pick up the phone and find out exactly where things are at with the FDA, other approval jusristictions and wrt to trial design. We will be informed once ph3 is approved.

As far as a NASDAQ listing for RVX goes, I would love to see that but I think it would be crazy to obtain that until a phase 3 WITH FDA approval is received. I view this quiet, low volume period of time as somewhat akin to compressing a spring. Imagine the pop of an FDA phase 3 approval coinciding with a NASDAQ listing.

All JMO